Intellia Therapeutics Inc (NTLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$7.98
Buy
$7.99
$0.1082 (+1.37%)
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
Prices updated at 15 May 2025, 19:46 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| 26m | 30m | 43m | 58m | 33m | 52m | 36m | 58m | |
| - | - | - | - | - | - | - | - | |
| -70m | -91m | -106m | -137m | -268m | -458m | -515m | -534m | |
| -266.32 | -298.58 | -246.78 | -235.51 | -810.37 | -879.04 | -1,420.51 | -923.10 | |
| -68m | -85m | -100m | -134m | -268m | -474m | -481m | -519m | |
| -67m | -86m | -101m | -130m | -261m | -451m | -506m | -524m | |
| Sales, General and administrative | 28m | 32m | 41m | 44m | 71m | 90m | 116m | 126m |
| Interest expenses | - | - | - | - | - | - | - | - |
| Provision for income taxes | - | - | - | - | - | - | - | - |
| Operating expenses | 96m | 121m | 149m | 195m | 301m | 510m | 552m | 592m |
| Income before taxes | -68m | -85m | -100m | -134m | -268m | -474m | -481m | -519m |
| Net income available to common shareholders | -68m | -85m | -100m | -134m | -268m | -474m | -481m | -519m |
| -1.88 | -1.98 | -2.11 | -2.4 | -3.78 | -6.16 | -5.42 | -5.25 | |
| Net interest income | 2m | 6m | 7m | 2m | 1m | 9m | 50m | 48m |
| Advertising and promotion | - | - | - | - | - | - | - | - |
| Net investment income, net | - | - | - | - | - | - | - | - |
| Realised capital gains (losses), net | - | - | - | - | - | - | - | - |
| Total benefits, claims and expenses | - | - | - | - | - | - | - | - |
| Earnings per share (diluted) | -1.88 | -1.98 | -2.11 | -2.4 | -3.78 | -6.16 | -5.42 | -5.25 |
| Free cash flow per share | -1.9932 | -1.9418 | -1.9347 | -0.8207 | -3.276 | -4.7224 | -4.5711 | -3.7819 |
| Book value/share | 4.1488 | 6.0431 | 5.4913 | 4.9766 | 14.8632 | 9.471 | 11.1553 | 9.4347 |
| Debt equity ratio | - | - | 0.046798 | 0.063765 | 0.0624 | 0.092279 | 0.092125 | 0.217846 |
Balance sheet
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 355m | 325m | 289m | 617m | 769m | 1,217m | 998m | 640m |
| Current liabilities | 31m | 41m | 36m | 64m | 126m | 127m | 115m | 111m |
| Total capital | 301m | 278m | 270m | 527m | 1,040m | 1,236m | 1,050m | 872m |
| Total debt | - | - | 18m | 39m | 74m | 131m | 115m | 210m |
| Total equity | 301m | 278m | 270m | 527m | 1,040m | 1,236m | 1,050m | 872m |
| Total non current liabilities | - | - | - | - | - | - | - | - |
| Loans | - | - | - | - | - | - | - | - |
| Total assets | 376m | 347m | 334m | 676m | 1,294m | 1,520m | 1,301m | 1,191m |
| Total liabilities | - | - | - | - | - | - | - | - |
| Cash and cash equivalents | 341m | 59m | 57m | 160m | 123m | 524m | 227m | 189m |
| Common stock | 42m | 44m | 50m | 66m | 74m | 87m | 93m | 102m |
Cash flow
Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash at beginning of period | 273m | 341m | 59m | 57m | 165m | 125m | 535m | 240m |
| Cash dividends paid | - | - | - | - | - | - | - | - |
| -75m | -68m | -110m | -53m | -238m | -392m | -408m | -355m | |
| Investments (gains) losses | -10m | -261m | 25m | -214m | -551m | 160m | -31m | 126m |
| 341m | 59m | 57m | 165m | 125m | 535m | 240m | 203m | |
| Net income | - | - | - | - | - | - | - | - |
| -65m | -61m | -103m | -50m | -225m | -333m | -394m | -349m | |
| -10m | -6m | -7m | -4m | -13m | -58m | -14m | -6m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
